Gilead Sciences (GILD) UBS Global Biopharma Conference 2026 summary
Event summary combining transcript, slides, and related documents.
UBS Global Biopharma Conference 2026 summary
20 Nov, 2026HIV prevention growth and launches
Yeztugo, a once-every-six-month subcutaneous HIV prevention injection, is targeting $1B in 2026 sales, raised from initial guidance of ~$800M; launch metrics are at or ahead of expectations.
More than 70% of Yeztugo users returned for a second injection; two-thirds to three-quarters of switchers came from daily oral therapies, with prevention-naive users also starting treatment.
HIV prevention is a ~$4B business: Yeztugo is expected to generate ~$1B in sales this year and DESCOVY ~$3B; market volume has grown 14%-15% in recent years.
A weekly oral Yeztugo has a February PDUFA date; a once-yearly intramuscular injection is expected in 2028, expanding the portfolio to four branded prevention options.
US prevention use is 600,000-700,000 people versus CDC-estimated potential of 2.2M; the weekly pill could shift patients from branded and generic daily pills to branded therapy.
Anito-cel and other launches
Anito-cel has a December 23 PDUFA date; management expects a fourth-line-plus label and is confident in approval, citing efficacy at least competitive with a differentiated safety profile.
Updated anito-cel data, including Kaplan-Meier curves, are due at ASH; second-line-plus studies are fully enrolled, with data expected next year. That market is ~4x larger than fourth-line-plus.
Authorized treatment centers are expected to be ready at launch; formulary access may take one or two quarters, with a strong market position targeted within 18 months. Three global manufacturing facilities support supply.
Other ongoing launches include Yeztugo, Bixlenvo in HIV treatment, Livdelzi in PBC and Trodelvy in first-line triple-negative breast cancer; three additional launches are expected.
Business outlook
The base business grew 7%-9% over the prior three years and is expected to grow 10%-11% in 2026; VEKLURY sales are expected to be ~$300M, down from a $5.6B peak.
Biktarvy grew 10% YoY in Q3; HIV growth is primarily demand-led, while favorable prevention pricing from payer mix may moderate.
A $1.5B Biktarvy drug-price negotiation headwind is expected in 2028, but management expects HIV, total business and EPS to grow that year.
Guidance is expected on the year-end call in late January or early February; management cited no patent cliffs through 2036 and a strong growth setup for the next decade.
Latest events from Gilead Sciences
- Long-acting HIV options and diversified pipelines underpin growth through 2030 and beyond.GILD
Jefferies Global Healthcare Conference - Anito-cel launch plans pair 200 centers with an earlier-line filing targeted for 2027.GILD
8th Annual Wolfe Research Healthcare Conference - Base sales grew 16%, lifting guidance; acquisitions and BIKTARVY pricing weigh on outlook.GILD
Q3 2026 - HIV and Oncology growth offset Veklury declines; FY24 ex-Veklury sales guidance rises.GILD
Q4 2023 - Strong HIV growth, new launches, and oncology advances drive portfolio momentum.GILD
Morgan Stanley 24th Annual Global Healthcare Conference - HIV and cell therapy franchises expand with new launches, pipeline progress, and strategic acquisitions.GILD
12th Annual Cantor Fitzgerald Global Healthcare Conference - Diversified pipeline advances in HIV, oncology, and inflammation set up multiple launches and key data.GILD
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 sales rose 10%, led by HIV and oncology, but IPR&D charges drove a net loss.GILD
Q2 2026 - Q3 2025 saw 3% revenue growth, strong HIV/liver sales, and a key Biktarvy patent win.GILD
Q3 2025